Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 17, 2019 09:00 ET | Source: INmune Bio, Inc.

INmune Bio Announces Final Phase I Clinical Data for its Soluble TNF Inhibitor, INB03, Demonstrates Efficacy and Safety; INB03 is Advancing to Phase II Trials

Phase II program to focus on women with trastuzumab resistant HER2+ breast cancer LA JOLLA, Calif. , Dec. 17, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc., an immunology company developing therapies...
December 02, 2019 09:00 ET | Source: INmune Bio, Inc.

INmune Bio, Inc. Announces First Alzheimer’s Disease Patient Dosed in XPro1595 Study

Neuroinflammation targeted in XPro1595 Phase Ib clinical trial LA JOLLA, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company...
November 26, 2019 06:00 ET | Source: INmune Bio, Inc.

INmune Bio Inc. to Discuss Potential New Alzheimer’s Disease Treatments in CTAD Pre-Conference Webinar

INmune Bio’s CEO, Dr. R.J. Tesi, will moderate a panel of experts from neuroscience research, clinical trials, and Alzheimer’s drug development. LA JOLLA, Calif., Nov. 26, 2019 (GLOBE...
November 19, 2019 09:00 ET | Source: INmune Bio, Inc.

INmune Bio, Inc. Strengthens Board of Directors with Appointment of Veteran Finance Executive Marcia Allen

LA JOLLA, Calif., Nov. 19, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company developing treatments that harness the patient’s innate immune system to fight disease,...
November 08, 2019 16:00 ET | Source: INmune Bio, Inc.

INmune Bio, Inc. Reports Third Quarter 2019 Financial Results and Provides Shareholder Update

LA JOLLA, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), an immunology company developing treatments that harness the patient’s innate immune system to...
October 21, 2019 15:00 ET | Source: INmune Bio, Inc.

INmune Bio, Inc. Announces Potentially Strong Link Between Obesity and Alzheimer's Disease at the Society for Neuroscience 49th Annual Meeting

Dr. Malú Tansey’s new data highlighted at today’s press conference LA JOLLA, Calif., Oct. 21, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company developing treatments...
October 17, 2019 09:00 ET | Source: INmune Bio, Inc.

INmune Bio, Inc. Announces Presentation of Data Related to its Lead Compound XPro1595 at the Society for Neuroscience’s Annual Meeting

Data on Neuroinflammation and Alzheimer’s Disease to be Presented by Dr. Malú Tansey; Presentation Selected for Meeting’s Press Conference LA JOLLA, Calif., Oct. 17, 2019 (GLOBE NEWSWIRE) --...
October 08, 2019 09:00 ET | Source: INmune Bio, Inc.

INmune Bio Inc. to Present at Advances in Immuno-Oncology USA Congress and at World Immunotherapy Congress in October

LA JOLLA, Calif., Oct. 08, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight...
September 24, 2019 10:20 ET | Source: INmune Bio, Inc.

CEO of INmune Bio Inc. Discusses Company Accomplishments at Nasdaq’s MarketSite and Announces Presentation at World Immunotherapy Congress

La Jolla, CA., Sept. 24, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight...
September 23, 2019 09:03 ET | Source: INmune Bio, Inc.

INmune Bio to Present XPro1595 for Treating Neuroinflammation in Alzheimer’s Disease at 2019 Alzheimer’s Association International Conference (AAIC) Satellite Symposium

LA JOLLA, Calif., Sept. 23, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunotherapy company developing treatments which harness the patient’s innate immune system to fight...